IUPAC

The project under the title “Analogue-based Drug Discovery” has been successfully completed between 2003-2005 and the book, which has been published in 2006 by Wiley-VCH, was well received and all the copies have been sold in 18 months. Based on the positive feedbacks (see eg. M. Cowart, J. Med. Chem. 2006, 49, 4799) a continuation is needed.

The second volume of the book would consist of the following chapters:

I. General Aspects
I-1. Optimizing  Therapy  by  Analogues  (J. Fischer, CR. Ganellin, and EM. Alapi)   
I-2.   Analogues  and  Standalone  Drugs  (J. Fischer, CR. Ganellin, A. Ganesan, and J. Proudfoot)
I-3.   Lead  and  Drug  Optimization   (J. Fischer, CR. Ganellin, and J. Proudfoot)
I-4.   Molecular  Modeling  in  ABDD   (G. Ferenczy)  
I-5.   The  Impact  of  Natural  Products  upon  Modern Drug  Discovery  (A. Ganesan)
I-6.   Monoterpenoid  Indole  Alkaloids  (A. Nemes)  
I-7.   Paclitaxel  analogue  (P. Erhardt and  M. El-Dakdouki)  
I-8.   Issues  for  Patenting  of  Analogues  (S. Smith)

II. Analogue Classes
II-1. Beta2 agonists (G. Gaviraghi)
II-2. M3  muscarinic antagonists  (M. Grauert, P. Casarosa, and MP. Pieper)
II-3. SSRIs   (D. Rotella  and WE. Childers)  
II-4. Progestogens  (Z. Tuba, S. Maho,  J. Csorgei and C. Molnar)  
II-5. DPP-IV inhibitors  (JU. Peters  and P. Mattei)   
II-6. PDE5  inhibitors  (H. Haning and E. Bischoff)  
II-7. Serotonin  and  norepinephrine reuptake inhibitors  (M. Abou-Gharbia and W. Childers)
II-8. Anthracyclines (FA. Arcamone)
II-9. Rifampicin  analogues  (E. Selva  and G. Lancini)

III. Case Studies
III-1. Eplerenone (J. Kalvoda and M. De Gasparo)
III-2. Lapatinib (K. Lackey)
III-3. Dasatinib (J. Das and JC Barrish)
III-4. Conazoles (J. Heeres, P. Lewi, and L. Meerpoel)
III-5. Clevudine (CK. Chu)
III-6. Rasagiline (M. Youdim) 
III-7. Liraglutide (LB. Knudsen)
III-8. Tipranavir (S. Thaisrivongs, J. Strohbach, and S. Turner)
III-9. Rilpivirine (J. Guillemont  and  J. Heeres)

The second volume will discuss a broad spectrum of discoveries of anticancer, antifungal, antiviral, cardiovascular, CNS, diuretic, hormonal, respiratory, diabetes type 2 drugs.  The majority of the authors, who come from ten different countries, were also involved as inventor.

This project started in May 2008 and according to the chapters that are planned, 42 authors will participate.

> project announcement published in Chem. Int. Mar-Apr 2009

last update 20090320